Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS

References

• Silverman SL, Piziak VK, Chen P, et al. Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. J Rheumatol 2005;32:2405-9
   PubMed Web of Science ®Google Scholar
• Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998;128:793-800
   PubMed Web of Science ®Google Scholar
• Jarvik JG, Deyo RA. Diagnostic evaluation of low back pain with emphasis on imaging. Ann Intern Med 2002;137:586-97
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1--34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Saag KG, Shane E, Boonen S, et al. Teriparatide compared with alendronate for the treatment of glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39
   PubMed Web of Science ®Google Scholar
• Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004;164:2024-30
   PubMed Web of Science ®Google Scholar
• Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005;20:1507-13
   PubMed Web of Science ®Google Scholar
• Nevitt MC, Chen P, Dore RK, et al. Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 2006;17:273-80
   PubMed Web of Science ®Google Scholar
• Nevitt MC, Chen P, Kiel DP, et al. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int 2006;17:1630-7
   PubMed Web of Science ®Google Scholar
• Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis following teriparatide: final results of the randomized, controlled European study of Forsteo (EUROFORS). J Bone Miner Res 2009;24:726-36
   PubMed Web of Science ®Google Scholar
• Obermayer-Pietsch B, Marin F, McCloskey EV, et al. for the EUROFORS Investigators. Effects of two years of daily teriparatide treatment on bone mineral density in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008;23:1591-600
   PubMed Web of Science ®Google Scholar
• Boonen S, Marin F, Obermayer-Pietsch B, et al. for the EUROFORS Investigators. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008;93:852-60
   PubMed Web of Science ®Google Scholar
• Minne H, Audran M, Simoes ME, et al. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study. Curr Med Res Opin 2008;24:3117-28
   PubMed Web of Science ®Google Scholar
• Sriwatanakul K, Kelvie W, Lasagna L, et al. Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther 1983;34:234-9
   PubMed Web of Science ®Google Scholar
• McClung MR, San Martin J, Miller PD, et al. Opposite bone remodelling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-8
   PubMed Web of Science ®Google Scholar
• Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17
   PubMed Web of Science ®Google Scholar
• Body J-J, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528-35
   PubMed Web of Science ®Google Scholar
• Ste-Marie LG, Schwartz SL, Hossain A, et al. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 2006;21:283-91
   PubMed Web of Science ®Google Scholar
• Genant HK, Halse J, Briney WG, et al. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin 2005;21:1027-34
   PubMed Web of Science ®Google Scholar
• Begerow B, Pfeifer M, Pospeschill M, et al. Time since vertebral fracture: an important variable concerning quality of life in patients with postmenopausal osteoporosis. Osteoporos Int 1999;10:26-33
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Rajzbaum G, Jakob F, et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009;85:484-93
   PubMed Web of Science ®Google Scholar
• Nakajima A, Shimoji N, Shiomi K, et al. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone[1-34]. J Bone Miner Res 2002;17:2038-47
   PubMed Web of Science ®Google Scholar
• Dobolyi A, Ueda H, Uchida H, et al. Anatomical and physiological evidence for involvement of tuberoinfundibular peptide of 39 residues in nociception. Proc Natl Acad Sci USA 2002;99:1651-6
   PubMed Web of Science ®Google Scholar
• Nevitt MC, Thompson DE, Black DM, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Arch Intern Med 2000;160:77-85
   PubMed Web of Science ®Google Scholar
• Iwamoto J, Takeda T, Sato Y, et al. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption and chronic back pain in postmenopausal women with osteoporosis. Clin Rheumatol 2004;23:383-9
   PubMed Web of Science ®Google Scholar
• Miller PD, Shergy WJ, Body J-J, et al. Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol 2005;32:1556-62
   PubMed Web of Science ®Google Scholar
• Armingeat T, Brondino R, Pham T, et al. Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. Osteoporos Int 2006;17:1659-65
   PubMed Web of Science ®Google Scholar
• Gangji V, Appelboom T. Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol 1999;18:266-7
   PubMed Web of Science ®Google Scholar
• Knopp JA, Diner BM, Blitz M, et al. Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 2005;16:1281-90
   PubMed Web of Science ®Google Scholar
• Silverman SL, Azria M. The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 2002;13:858-67
   PubMed Web of Science ®Google Scholar
• Lyritis GP, Trovas G. Analgesic effects of calcitonin. Bone 2002;30(Suppl. 5):71S-74S
   Google Scholar
• Papadokostakis G, Damilakis J, Mantzouranis E, et al. The effectiveness of calcitonin on chronic back pain and daily activities in postmenopausal women with osteoporosis. Eur Spine J 2006;15:356-62
   PubMed Web of Science ®Google Scholar
• Payne R. Mechanisms and management of bone pain. Cancer 1997;80(Suppl. 8):1608-13
   PubMed Web of Science ®Google Scholar
• Bruyère O, Delferriere D, Roux C, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008;67:335-39
   PubMed Web of Science ®Google Scholar
• Scharla S, Oertel H, Helsberg K, et al. Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration. Curr Med Res Opin 2006;22:2392-402
   Google Scholar
• Sadreddini S, Molaeefard M, Noshad H, et al. Efficacy of raloxifen in treatment of fibromyalgia in menopausal women. Eur J Intern Med 2008;19:350-5
   PubMed Web of Science ®Google Scholar
• Papadokstakis G, Katonis P, Damilakis J, et al. Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis?. Eur Spine J 2005;14:977-81
   PubMed Web of Science ®Google Scholar